With the FDA approving multiple novel new therapies over the past couple of years, we should expect to see more of the same moving forward. But that innovation comes at a price, and even with all the pressure to keep drug prices down, the pharmaceutical industry likely will continue to offer products at higher price points than ever before. In this context, drug pricing and innovation will continue to dominate the specialty drug headlines.
- Abstract, Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Specialty Pharmacy
- Datapoint, Drug Benefits
- Drug Benefits